Primary immunodeficiency
ORPHA:101997Category
Эпидемиология14
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Point prevalence | 1-9 / 100 000 | — | Europe | Class only |
| Point prevalence | 1-9 / 100 000 | 6.8 | Norway | Value and class |
| Point prevalence | 1-5 / 10 000 | 11 | France | Value and class |
| Point prevalence | 1-9 / 100 000 | 3.6 | Spain | Value and class |
| Point prevalence | 1-9 / 100 000 | 2.6 | Netherlands | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.84 | United Kingdom | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.79 | Italy | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.38 | Germany | Value and class |
| Point prevalence | 1-9 / 100 000 | 2 | Turkey | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.33 | Poland | Value and class |
| Point prevalence | 1-9 / 100 000 | 5.6 | Australia | Value and class |
| Point prevalence | 1-9 / 100 000 | 4.9 | New Zealand | Value and class |
| Point prevalence | 1-9 / 100 000 | 1.1 | Korea, Republic of | Value and class |
| Point prevalence | 1-9 / 100 000 | 4.5 | Oman | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)